Skip to main content

Table 1 Characteristics of the patients at baseline and according to the primary end point occurrence

From: Clinical outcomes after primary prevention defibrillator implantation are better predicted when the left ventricular ejection fraction is assessed by cardiovascular magnetic resonance

 N = 173Death or ADTpp for survival
Yes (n = 66)No (n = 107)
Follow-up, months (mean ± SD)50,3 ± 30,352,5 ± 28,746,7 ± 32,70,223 
Age, years (mean ± SD)59 ± 1260 ± 1358 ± 110,554(≥ vs < 58) 0,979
Male, n (%)149 (86)62 (94)87 (81)0,0230,206
BMI, kg/m2 (mean ± SD)27.2 ± 527.9 ± 426.9 ± 50.476(≥ vs < 27) 0.730
ICM, n (%)120 (69)54 (82)66 (62)0,0060,046
Revascularization, n(%)
 PCI74 (62)33 (59)41 (64)0.1320.026
 CABG14 (12)10 (18)4 (6)
 None32 (27)13 (23)19 (30)
Diabete mellitus, n (%)40 (23)14 (21)26 (24)0,7120,819
Hypertension, n (%)49 (28)24 (36)25 (23)0,0820,046
Smokers, n (%)64 (37)28 (42)36 (34)0,2600,918
COPD (Gold ≥2), n (%)18 (10)10 (14)8 (8)0.2030.316
Cancer, n (%)4 (2.3)2 (3)2 (2)10.299
AF, n (%)35 (20)20 (30)15 (14)0,0120,196
NYHA class, n (%)
 I28 (16)9 (14)19 (18)0,270II vs I: 0,508
 II99 (57)35 (53)64 (60)III vs I: 0,079
 III46 (27)22 (33)24 (22)III vs I + II: 0,054
Heart rate, ppm (mean ± SD)69 ± 1666 ± 1371 ± 180,1080,354
QRS duration, ms (mean ± SD)124 ± 33121 ± 32125 ± 340,4130,384
eGFR, ml/min (mean ± SD)67.4 ± 20.359.5 ± 17.767.4 ± 19.90.008(≥ vs < 60) 0.932
CKD 3b, n (%)25 (15)15 (22)10 (10)0.030.316
Betablockers, n (%)163 (94)64 (97)99 (93)0,3210,270
ARB or ACEI, n (%)163 (94)62 (94)101 (94)10000,661
Diuretics, n (%)124 (72)47 (71)77 (72)10000,939
MRA, n (%)105 (61)41 (62)64 (60)0,8730,556
Resynchronization therapy, n (%)56 (32)21 (32)35 (33)10000,978
MAGGIC Score (mean ± SD)20 ± 622 ± 719 ± 50.040(≥ vs < 19) 0.105
Sodium, mmol/l (mean ± SD)138 ± 3137 ± 3138 ± 30.071(≥ vs < 138) 0.920
BNP, pg/ml (mean ± SD)625 ± 622674 ± 511592 ± 6890.449(≥ vs < 400) 0.462
Hematocrit, % (mean ± SD)40 ± 1939 ± 441 ± 40.042(≥ vs < 41) 0.035
2D echo-LVEF, % (mean ± SD)27,5 ± 6,327 ± 628 ± 70,5000,256
2DEcho-LVEF< 26, n (%)63 (36)30 (46)33 (33)0,1410,052
CMR-LVEF, % (mean ± SD)23,4 ± 6,722 ± 724 ± 70,0870,010
CMR-LVEF< 22, n (%)60 (35)28 (42)32 (30)0,1020,005
LGE, n(%)133 (77)58 (87)75 (71)0,0170,058
LGE and CMR-LVEF< 22, n(%)44 (25)26 (39)18 (18)0,002< 0,001
LGE and 2D echo-LVEF< 26, n(%)50 (29)28 (42)22 (22)0,0100,010
Complications, n (%)23 (13)9 (14)14 (13)10000,695
Infections, n (%)7 (4)1 (1)6 (6)0.2450.702
Other complications16 (9)8 (1)8 (7)
Inappropriate device therapies, n(%)7 (4)7 (10)0 (0)0.0010.730
  1. Continuous variables are normally distributed, expressed as mean and standard deviation. AF: atrial fibrillation; ACEI angiotensine converting enzyme inhibitor; ARB angiotensine receptor blockers; BMI body mass index; BNP brain natriuretic peptide; CABG coronary artery bypass graft; CKD 3b chronic kidney disease stage 3b defined by eGFR< 45 ml/min; CMR-LVEF cardiovascular magnetic resonance left ventricular ejection fraction; COPD chronic obstructive pulmonary disease; eGFR estimated glomerular filtration rate; ICM ischemic cardiomyopathy; LGE Late gadolinium enhancement; MAGGIC meta-analysis global group in chronic heart failure; MRA Mineralocorticoid receptor antagonist; NYHA New-York Heart Association; ppm pulse per minute; PCI percutaneous coronary intervention; SD standard deviation; 2DEcho-LVEF two dimensional echocardiography left ventricular ejection fraction